期刊文献+

结直肠肿瘤患者手术分离易感菌株的药物敏感性分析 被引量:3

Drug Susceptibility of Susceptible Strains Isolated from Surgical Samples of Patients with Colorectal Cancer
暂未订购
导出
摘要 目的:对不同手术方式组中分离的易感菌株的药物敏感性进行分析,并根据结果为临床提供选择围术期预防性应用抗菌药物方案,以减少耐药率,降低术后手术部位感染(SSI)的发生率.方法:对我院结直肠外科164例患者分离的易感菌株,用VITEK-32全自动微生物分析系统进行菌种鉴定,按临床和实验室标准协会(CLSI)制定的指导原则进行药物敏感性试验及结果判断.通过分析不同手术方式及不同细菌来源的药物敏感性情况,对药物敏感性试验结果进行统计和分析.结果:革兰阴性菌中产超广谱口-内酰胺酶(ESBL)菌株占33.2% (115/346),以产ESBL大肠埃希菌为主,占43.4% (96/221).在组织黏膜、腹腔液、引流液3组样本分离的大肠埃希菌株药物敏感性试验结果总体显示:对阿米卡星、头孢西丁、碳青霉烯类、含β-内酰胺酶药物敏感率较高,引流液分离菌株敏感率均在80% ~ 100%.结论:样本主要分离以大肠埃希菌为主的革兰阴性菌,大肠埃希菌耐药率在3组样本中逐次增高与产ESBL大肠埃希菌分离率增加有关,产ESBL大肠埃希菌对第1—4代头孢菌素如头孢吡肟耐药率高,对阿米卡星、头孢西丁、含β-内酰胺酶药如哌拉西林/他唑巴坦、亚胺培南等碳青霉素类药敏感率较高.建议临床把现常用的第3代头孢菌素改用能同时覆盖肠杆菌科细菌和厌氧菌的头孢西丁等头霉素类药作为围术期预防用药品种.考虑手术部位存在厌氧菌株,必要时或与甲硝唑联用加强抗厌氧菌感染. OBJECTIVE:To analyze the drug sensitivity of the susceptible strains from different surgical groups of colorectal cancer patients and with the analytic results as reference to provide perioperative prophylactic antibiotic use regimens to reduce drug resistance and incidence of surgical site infection (SSI).METHODS:The susceptible strains isolated from one hundred and sixty-four colorectal cancer patients were identified using VITEK-32 automatic microbiological analyzer,and drug susceptibility test was performed and the results were judged in accordance with the guiding principle issued by CLSI.The drug susceptibility test on different bacteria from different surgical procedure was analyzed statistically.RESULTS:33.2% (115/346)of the isolated G-bacteria produced ESBLs,most of which were E.coli.(43.4%,96/221).The E.coli from mucosal tissue,peritoneal fluid and fluid drainage samples were sensitive to Amikacin,Cefoxitin,Carbapenems and β-Lactamase-containing drugs and the susceptibility rates of the strains from fluid drainage all stood at 80%-100%.CONCLUSION:G-bacteria,mainly E.coli were the most commonly detected strain from three types of samples.The increase of drug resistance of E.coli in three samples in order(mucosa,intraoperative fluid to fluid one day after surgery)was associated with increasing in the isolating rate of ESBLs.ESBLs-producing E.coli were resistant to first,second,third and fourth generations of Cephalosporins but sensitive to Amikacin,Cefoxitin,β-Lactamase-containing drugs such as Piperacillin/Tazobactam,Imipenem and other CarbaDenems.It is advisable to use Cephamycins that are effective to Enterobacteriaceae and anaerobic bacteria such as Cefoxitin in the setting of perioperative prophylactic use.Metronidazole may be used concurrently if necessary in order to prevent anaerobic infection.
出处 《中国医院用药评价与分析》 2014年第2期139-141,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 广东省科技计划项目(编号:2011B061300089)
关键词 结直肠肿瘤 手术方式 围术期 易感菌株 药物敏感性 Colorectal cancer Surgical procedure Perioperative period Susceptible strain Drug susceptibility
  • 相关文献

参考文献7

  • 1Suzuki T, Sadahiro S, Maeda Y, et al. Optimal duration of prophylactic antibiotic administration for elective colon cancer surgery : A randomized, clinical trial [J]. Surgery, 2011,149(2) : 171-178.
  • 2Jeong WK, Park JW, Lim SB, et al. Cefotetan versus conventional triple antibiotic prophylaxis in elective colorectal cancer surgery [ J ]. J Korean Med Sci, 2010,25 (3) :429-434.
  • 3何文英,宋福玲,朱荣贤,伍萍.外科手术后医院感染及其病原菌耐药性变迁[J].中国感染控制杂志,2004,3(4):330-332. 被引量:2
  • 4高硕,张红梅,蒋若冰.氟喹诺酮类药物的研究进展[J].沈阳药科大学学报,2011,28(9):756-759. 被引量:21
  • 5Arias CA, Murray BE. Antibiotic-resistant bugs in the 21 st century-a clinical super-challenge [ J ]. N Engl J Med, 2009,360(5 ) :439-443.
  • 6高磊,吕媛.Mohnarin 2009年度报告:非ICU住院感染患者细菌耐药监测[J].中国临床药理学杂志,2011,27(5):373-379. 被引量:12
  • 7卫生部办公厅.关于抗菌药物临床应用管理有关问题的通知[S].卫办医政发[2009]38号.

二级参考文献25

  • 1张健騑,李跃龙,陈鲜花,余永鹏,王刚,尹烨华,谭滇湘.禽致病性大肠杆菌对氟喹诺酮类药物交叉耐药性研究[J].广东农业科学,2005,32(2):74-76. 被引量:12
  • 2蔡德山,谢新明.谈头孢菌素类抗生素基础药物市场[J].中国医药技术经济与管理,2009(11). 被引量:7
  • 3王丽,朱珊,刘彩虹.氟喹诺酮药物不良反应108例分析及合理应用[J].实用诊断与治疗杂志,2006,20(1):44-46. 被引量:12
  • 4李仲兴 郑家齐.诊断细菌学[M].香港:黄河文化出版社,1992.295-297.
  • 5SMITH A,PENNEFATHER P M,KAYE S B,et al. Fluoroquinolones: place in ocular therapy [ J ]. Drugs, 2001,61 (6) :747 -761.
  • 6BLONDEAU J M. Gatifloxacin:a new fluoroquinolo- ne E J ]. Expert Opin Investig Drugs, 2000, 9 ( 8 ) : 1877 - 1895.
  • 7DRLICA K, XU C, WANG J Y, et al. Fluoroquinolone action in mycobacteria: similarity with effects in Esch- erichia coli and detection by cell lysate viscosity [ J ]. Antimicrob Agents Chemother, 1996,40 ( 7 ) : 1594 - 1599.
  • 8DRLICA K. Mechanism of fluoroquinolone action [ J ]. Curr Opin Microbiol, 1999,2 (5) :504 - 508.
  • 9SMITH J L, FRATAMICO P M. Fluoroquinolone re- sistance in campylobacter[J]. J Food Prot, 2010,73 (6) :1141 - 1152.
  • 10HOOTON T M. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection[ J ]. Int J Antimicrob Agents,2003,22 ( Suppl 2 ) : 65 - 72.

共引文献114

同被引文献15

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部